 |
|
|
| |
Antiviral activity and tolerability of BIT225 plus pegylated interferon alfa-2b and weight-based ribavirin for 28 days in HCV treatment-naïve, genotype 1, mono-infected patients
|
| |
| |
Reported by Jules Levin
HepDART - December 6, 2011
T Tanwandee1, C Luscombe2, C Achenbach3, G Ewart2, M Miller2 , J Wilkinson2 and R Murphy3 1 Siriraj Hospital, Thailand; 2Biotron Limited, Australia;3 Northwestern University USA
|
| |
|
|
|
|
|
